adplus-dvertising
Connect with us

Business

Clear link between AstraZeneca and rare blood clots in brain, EMA vaccine chief says – National Post

Published

 on


‘In my opinion, we can now say it,’ said Marco Cavaleri, chair of the vaccine evaluation team at the European Medicines Agency

Article content

There is a link between AstraZeneca’s COVID-19 vaccine and very rare blood clots in the brain but the possible causes are still unknown, a senior official for the European Medicines Agency (EMA) said in an interview published on Tuesday.

“In my opinion we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction,” Marco Cavaleri, chair of the vaccine evaluation team at the EMA, told Italian daily Il Messaggero when asked about the possible relation between the AstraZeneca shot and cases of brain blood clots.

Cavaleri added that the EMA would say there is a link although the regulator would not likely be in a position this week to give an indication regarding the age of individuals to whom the AstraZeneca shot should be given.

He did not provide evidence to support his comments.

AstraZeneca was not immediately available for comment. It has said previously its studies have found no higher risk of clots because of the vaccine.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

The regulator has consistently said the benefits outweigh the risks as it investigates 44 reports of an extremely rare brain clotting ailment known as cerebral venous sinus thrombosis (CVST) out of 9.2 million people in the European Economic Area who have received the AstraZeneca vaccine.

The World Health Organization has also backed the vaccine.

The EMA said last week that its review had at present not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events. A causal link with the vaccine is not proven, but is possible and further analysis is continuing, the agency said.

A high proportion among the reported cases affected young and middle-aged women but that did not lead EMA to conclude this cohort was particularly at risk from AstraZeneca’s shot.

The EMA is expected to give an update of its investigation on Wednesday.

Some countries, including France, Germany and the Netherlands, have suspending the use of the vaccine in younger people while the investigations continue.

Scientists are exploring several possibilities that might explain the extremely rare brain blood clots that occurred in individuals in the days and weeks after receiving the AstraZeneca vaccine.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

European investigators have put forward one theory that the vaccine triggers an unusual antibody in some rare cases; others are trying to understand whether the cases are linked with birth control pills.

But many scientists say there is no definitive evidence and it is not clear whether or why AstraZeneca’s vaccine would cause an issue not shared by other vaccines that target a similar part of the coronavirus.

In a separate interview, Armando Genazzani, a member of the EMA’s Committee for Medicinal Products for Human Use (CHMP), told La Stampa daily that it was “plausible” that the blood clots were correlated to the AstraZeneca vaccine.

Some countries limit AstraZeneca vaccine use amid concern over blood clots

Some countries are restricting use of the AstraZeneca vaccine against COVID-19 while others have resumed inoculations, as investigations into reports of rare, and sometimes severe, blood clots continue.

The European Medicines Agency and the World Health Organization have said the benefits outweigh the risks, but are monitoring the situation.

AstraZeneca said in March its vaccine was 76% effective in preventing symptomatic infections in a U.S. trial, and that studies did not indicate higher risks of clotting.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

VACCINE BEING USED, WITH OR WITHOUT RESTRICTIONS

AUSTRALIA:

Will continue its inoculation program with the shot despite a blood clotting case reported on April 2, health officials said on April 3.

AUSTRIA:

Resumed use.

BULGARIA:

Resumed inoculations from March 19.

CYPRUS:

Cyprus resumed inoculations on March 19.

CANADA:

To pause offering vaccine to people aged under 55 and require a new analysis of the shot’s benefits and risks based on age and gender.

FRANCE:

Approved resumed use of the vaccine on March 19, but said it should only be given to people aged 55 and over.

FINLAND:

Resumed using the AstraZeneca vaccine from March 29, but will only give it to people aged 65 and over.

GEORGIA:

Has limited the use of the vaccine after a nurse died of anaphylactic shock, and vaccinations will continue only in full-fledged medical centres, news agency TASS reported on March 19.

GERMANY:

From March 31, Germany limited use of the shot to people over 60 and high-priority groups, following further reports of a rare brain blood disorder. On April 1, Germany’s vaccine commission recommended that people under 60 who have had a first shot of AstraZeneca’s vaccine should receive a different product for their second dose.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

ICELAND:

Resumed use on March 25 after suspending it on March 11.

INDONESIA:

Resumed using the vaccine on March 22 but warned against the use of the vaccine in people with a low blood platelet count.

IRELAND:

Resumed use after EMA recommendation.

ITALY:

Resumed use on March 19, and Italians who decline to be inoculated with it will be given an alternative later.

LATVIA:

Said would restart administering the shots from March 19.

LITHUANIA:

Restarted use on March 19.

NETHERLANDS:

Currently using the vaccine only for over 60s, either at a doctors’ surgery or by a doctor at nursing homes.

NORTH MACEDONIA:

Health Minister Venko Filipce said on March 31 that AstraZeneca shots would be limited to people aged over 60 as a precautionary measure.

ROMANIA:

Resumed use after the EMA assessment after temporarily stopping vaccinating people with one batch of the vaccine on March 11.

SOUTH KOREA:

President Moon Jae-in received the vaccine on March 23 ahead of an overseas trip, as the country inoculates senior citizens and health workers.

SPAIN:

Spain said on March 30 it would use the vaccine for people aged 55-65, and a day later said it would extend the vaccination to essential workers aged over 65.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

SWEDEN:

Resumed use of the vaccine on March 25 for people aged 65 and older, but restrictions are in place for Swedes under 65.

THAILAND:

Began use on March 15, with Prime Minister Prayuth Chan-ocha the first to be inoculated, after delaying rollout the week before.

USE SUSPENDED

CAMEROON:

Suspended administration of the vaccine it was scheduled to receive on March 20 as part of the global vaccines sharing scheme COVAX, the health ministry said.

DENMARK:

Will prolong its suspension of the shot by three weeks pending further investigations after its two-week pause ended on March 25. A local survey indicated that one in three Danes would decline to get the shot.

NORWAY:

Norway will delay a decision over the use of the vaccine, authorities said on March 26, with a decision expected by April 15.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Dollarama keeping an eye on competitors as Loblaw launches new ultra-discount chain

Published

 on

 

Dollarama Inc.’s food aisles may have expanded far beyond sweet treats or piles of gum by the checkout counter in recent years, but its chief executive maintains his company is “not in the grocery business,” even if it’s keeping an eye on the sector.

“It’s just one small part of our store,” Neil Rossy told analysts on a Wednesday call, where he was questioned about the company’s food merchandise and rivals playing in the same space.

“We will keep an eye on all retailers — like all retailers keep an eye on us — to make sure that we’re competitive and we understand what’s out there.”

Over the last decade and as consumers have more recently sought deals, Dollarama’s food merchandise has expanded to include bread and pantry staples like cereal, rice and pasta sold at prices on par or below supermarkets.

However, the competition in the discount segment of the market Dollarama operates in intensified recently when the country’s biggest grocery chain began piloting a new ultra-discount store.

The No Name stores being tested by Loblaw Cos. Ltd. in Windsor, St. Catharines and Brockville, Ont., are billed as 20 per cent cheaper than discount retail competitors including No Frills. The grocery giant is able to offer such cost savings by relying on a smaller store footprint, fewer chilled products and a hearty range of No Name merchandise.

Though Rossy brushed off notions that his company is a supermarket challenger, grocers aren’t off his radar.

“All retailers in Canada are realistic about the fact that everyone is everyone’s competition on any given item or category,” he said.

Rossy declined to reveal how much of the chain’s sales would overlap with Loblaw or the food category, arguing the vast variety of items Dollarama sells is its strength rather than its grocery products alone.

“What makes Dollarama Dollarama is a very wide assortment of different departments that somewhat represent the old five-and-dime local convenience store,” he said.

The breadth of Dollarama’s offerings helped carry the company to a second-quarter profit of $285.9 million, up from $245.8 million in the same quarter last year as its sales rose 7.4 per cent.

The retailer said Wednesday the profit amounted to $1.02 per diluted share for the 13-week period ended July 28, up from 86 cents per diluted share a year earlier.

The period the quarter covers includes the start of summer, when Rossy said the weather was “terrible.”

“The weather got slightly better towards the end of the summer and our sales certainly increased, but not enough to make up for the season’s horrible start,” he said.

Sales totalled $1.56 billion for the quarter, up from $1.46 billion in the same quarter last year.

Comparable store sales, a key metric for retailers, increased 4.7 per cent, while the average transaction was down2.2 per cent and traffic was up seven per cent, RBC analyst Irene Nattel pointed out.

She told investors in a note that the numbers reflect “solid demand as cautious consumers focus on core consumables and everyday essentials.”

Analysts have attributed such behaviour to interest rates that have been slow to drop and high prices of key consumer goods, which are weighing on household budgets.

To cope, many Canadians have spent more time seeking deals, trading down to more affordable brands and forgoing small luxuries they would treat themselves to in better economic times.

“When people feel squeezed, they tend to shy away from discretionary, focus on the basics,” Rossy said. “When people are feeling good about their wallet, they tend to be more lax about the basics and more willing to spend on discretionary.”

The current economic situation has drawn in not just the average Canadian looking to save a buck or two, but also wealthier consumers.

“When the entire economy is feeling slightly squeezed, we get more consumers who might not have to or want to shop at a Dollarama generally or who enjoy shopping at a Dollarama but have the luxury of not having to worry about the price in some other store that they happen to be standing in that has those goods,” Rossy said.

“Well, when times are tougher, they’ll consider the extra five minutes to go to the store next door.”

This report by The Canadian Press was first published Sept. 11, 2024.

Companies in this story: (TSX:DOL)

Source link

Continue Reading

Business

U.S. regulator fines TD Bank US$28M for faulty consumer reports

Published

 on

 

TORONTO – The U.S. Consumer Financial Protection Bureau has ordered TD Bank Group to pay US$28 million for repeatedly sharing inaccurate, negative information about its customers to consumer reporting companies.

The agency says TD has to pay US$7.76 million in total to tens of thousands of victims of its illegal actions, along with a US$20 million civil penalty.

It says TD shared information that contained systemic errors about credit card and bank deposit accounts to consumer reporting companies, which can include credit reports as well as screening reports for tenants and employees and other background checks.

CFPB director Rohit Chopra says in a statement that TD threatened the consumer reports of customers with fraudulent information then “barely lifted a finger to fix it,” and that regulators will need to “focus major attention” on TD Bank to change its course.

TD says in a statement it self-identified these issues and proactively worked to improve its practices, and that it is committed to delivering on its responsibilities to its customers.

The bank also faces scrutiny in the U.S. over its anti-money laundering program where it expects to pay more than US$3 billion in monetary penalties to resolve.

This report by The Canadian Press was first published Sept. 11, 2024.

Companies in this story: (TSX:TD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending